Viatris Inc. (VTRS) is a global healthcare company formed through the merger of Mylan and Upjohn (a division of Pfizer) in November 2020. Headquartered in Canonsburg, Pennsylvania, Viatris focuses on ...

But certainly, I think long-term, it can be a very, very strong opportunity. A third issue may relate to sotagliflozin, which Viatris opted to license from its developer Lexicon Therapeutics ...

Viatris' earnings beat was driven by effective cost management. For fiscal 2024, analysts anticipate Viatris to report an EPS of $2.68, down 8.5% from $2.93 in fiscal 2023 .

Shares of Viatris Inc. VTRS dropped 0.68% to $11.72 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 ...

Shares of Viatris Inc. VTRS shed 0.33% to $11.96 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,918.25 ...